Healthcare101

  Viral Vector Manufacturing Market in terms of revenue was estimated to be worth $5.5 billion in 2023 and is poised to reach $12.8 billion by 2028, growing at a CAGR of 18.2% from 2023 to 2028 according to a new report by MarketsandMarkets™. The growth of this market is driven by rising prevalence of target diseases and disorders, the availability of funding for gene therapy development, effectiveness of viral vectors in gene therapy delivery, and ongoing research into viral vector-based gene and cell therapies, leading to expanded applications and adoption of viral vector and plasmid DNA manufacturing technologies. ​ Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=89341986 Browse in-depth TOC on "Viral Vector Manufacturing Market" 363 - Tables 50 - Figures 332 – Pages The North America region catered the largest share of the viral vector and plasmid DNA manufacturing industry  in 2022. The viral vector and plasmid DNA manufacturin...

 Viral vector and plasmid DNA manufacturing market includes the products and services used for development and manufacturing of viral vector and plasmid DNA. Viral vectors are used to deliver genetic material into cells, while plasmid DNA is used to produce proteins or other molecules that can be used as vaccines or therapeutics. These technologies are being increasingly used to develop treatments for a range of diseases, including cancer, genetic disorders, and infectious diseases. The global viral vector manufacturing market in terms of revenue was estimated to be worth $5.5 billion in 2023 and is poised to reach $12.8 billion by 2028, growing at a CAGR of 18.2% from 2023 to 2028. Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=89341986 Market Dynamics 1. Market Drivers: Increasing Gene Therapy Approvals: The approval of gene therapies like Luxturna and Zolgensma has spurred interest and investment in viral vector manufacturing. Rising Preva...